CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
Year: 2025
Type: article
Language: en
Topic: Advanced Breast Cancer Therapies
Authors and affiliations:
raw_author_name: Nealia C. House
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA. NHouse@blueprintmedicines.com
Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Maxine M. Chen
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Sima Khazaei
raw_affiliation_strings: TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
TRACTION – Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Victoria Brown
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Philip Ramsden
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: David H. Peng
raw_affiliation_strings: TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
TRACTION – Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Sydney Moore
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Liang Yuan
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Rentian Wu
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Fangyang Wang
raw_affiliation_strings: TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
TRACTION – Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Linjie Luo
raw_affiliation_strings: Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Ningping Feng
raw_affiliation_strings: TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
TRACTION – Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Christopher A. Bristow
raw_affiliation_strings: TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
TRACTION – Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Timothy A. Yap
raw_affiliation_strings: Department of Investigational Cancer Therapeutics, Therapeutic Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Khandan Keyomarsi
raw_affiliation_strings: Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Joseph R. Marszalek
raw_affiliation_strings: TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
TRACTION – Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
raw_author_name: Scott Ribich
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Mikael L. Rinne
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Lakshmi B. Muthuswamy
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA
raw_author_name: Kerrie L. Faia
raw_affiliation_strings: Blueprint Medicines Corporation, Cambridge, MA, USA